Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oxytocin to enhance MRI-guided HIFU treatment for uterine fibroids and adenomyosis
2017-005022-38Phase 4Completed
- Sponsor
- Turku University Hospital
- Start
- Mar 2018
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of oxytocin in Fibromyoma (LM) and adenomyosis, sponsored by Turku University Hospital. Primary endpoint: Decrease in perfusion of uterine fibroid or adenomyosis. Started Mar 2018; status: completed.
02
Drugs
oxytocin
03
Conditions
Fibromyoma (LM)adenomyosis
Beyond the preview
Go deeper on 2017-005022-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-005022-38.